The Glycocalyx in COVID-19 Patients. A Pilot Study

NCT05137249 | Completed

• 1 other identifier: EK Nr: 1590/2020
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The damage of the endothelial glycocalyx is based on microvascular endothelial dysfunction and typical for critical clinical conditions like sepsis, trauma, bleeding, shock, as well as ARDS. We aim to generate first hints regarding the impact of covid-19 disease on the (damage) of the endothelial glycocalyx. Furthermore, we want to investigate the potential coagulopathies, which go along with shedding of the glycocalyx. The detection of and the relation between the severity of the disease, as well as the extent of the glycocalyx damage during the observational period, as well as the hemostatic alterations, are aim of the study.

Conditions

COVID-19; Endothelial Dysfunction; Coagulation Disorder

Keywords

glycocalyx, covid-19, ards, icu, coagulation,

Outcome Measures

Primary Outcomes (1)

• extent of endothelial damage

  circulating plasma syndecan-1 as surrogat parameter for endothelial damage is measures

  up to 2 months

Study Arms (2)

patients with COVID 19 disease

Patients diagnosed with and hospitalized due to COVID-19. Subgroups: ICU admitted COVID-19 + patients vs COVID 19 pts. at normal ward-

Healthy volunteers

healthy volnuteers

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients diagnosed and hospitalized with COVID 19 due to clinical symptoms.

You may qualify if:

• COVID-19 detected by PCR measures going along with clinical symptoms
• age \> 18 years

You may not qualify if:

• refusal of study participation

Sponsors & Collaborators

• Medical University of Vienna: lead

Study Sites (1)

Medical University of Vienna

Vienna, Austria

Location

MeSH Terms

Conditions

COVID-19; Hemostatic Disorders; Acute Lung Injury; Thrombosis

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhagic Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Lung Injury; Embolism and Thrombosis

Study Officials

• Judith Schiefer, MD PhD

  Medical University of Vienna, Department of Anesthesia, Intensive Care Medicine and Pain Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 24, 2021
• First Posted: November 30, 2021
• Study Start: December 1, 2020
• Primary Completion: March 1, 2021
• Study Completion: May 1, 2021
• Last Updated: November 30, 2021

Record last verified: 2021-11

Locations

AU (1)